Abstract

Background: Hemodialysis (HD) is the most extensively used dialysis method globally, and it necessitates vascular access. Arteriovenous fistulas (AVF), arteriovenous grafts, and central venous catheters (CVC), which can be tunneled or not, are all methods for gaining access. Vascular access is a major risk factor for bacteremia, hospitalization, and mortality among HD patients. The efficacy of Actolind solution in suppressing jugular catheter infection sites in patients with positive jugular catheter culture swab was investigated, as well as the efficiency of Actolind solution opposed to iodine. Methodology: This was a prospective, randomized, comparable efficacy clinical trial completed at the renal unit of the Port Sudan teaching hospital's renal dialysis center. The patient group was recruited from across the Red Sea State. A retrospective study of 50 End Stage Renal Disease (ESRD) patients who were either on upkeep HD or were scheduled to receive a kidney transplant as soon as possible. Sociodemographics, comorbidities, and microbiological growth outcomes were gathered prior to and after the interventional procedure. Results: According to the results, the male to female ratio was 4:1. There were 39 males and 11 females. All of the patients had ESRD, with 10 of them being hypertensive and diabetic, 34 being diabetic solely, and 16 being hypertension exclusively. Gram positive bacteria, gram negative bacteria, and yeasts constituted 32 (64%), 20 (40%), and 6 (12%) of the cultivars, respectively. Seven patients out of fifty had mixed infections (14%). Forty-one wound swab results after intervention were negative, while nine patients had persistent infection confirmed by positive cultures. Conclusion: Removal of CVC due to infection or catheter malfunction occurred less often with Actolind-based lock solutions. We present the prospective comparing Actolind - and iodine -based lock solutions yet. However, due to the retrospective observational nature of this study, conclusions with regard to superiority should be considering.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call